RespireRx Pharmaceuticals Inc. Revokes Securities Registration
RespireRx Pharmaceuticals Inc. is a prominent player in developing innovative treatments for diseases linked to neuronal signaling disruptions. Recently, the company disclosed the revocation of its securities registration as ordered by the SEC. Let's explore the implications of this decision and what future plans the company has in store.
The SEC Order Explained
On November 13, 2025, the SEC issued an Order concerning RespireRx Pharmaceuticals Inc., revoking the registration of its securities. This was a significant development for the company, which has been at the forefront of research into new pharmaceutical treatments.
The SEC's order came after unfiled periodic reports raised flags around compliance with the Securities Exchange Act of 1934. Notably, the Commission found that RespireRx failed to file required periodic reports since its last submission in 2023. This essential oversight contributed to the decision of the SEC to revoke the registration of the securities.
Understanding the Impacts of the Order
The revocation means that the common stocks of RespireRx, previously available on trading platforms, are no longer registered for trading. This step is designed to enhance investor protection by ensuring companies comply with reporting requirements. For RespireRx, it reflects the importance of maintaining current filings to avoid regulatory action.
However, the company affirmed that no monetary penalties would accompany this revocation, providing a silver lining in a challenging situation. The task now lies in navigating future compliance and registering its common stock once more to re-establish a marketplace presence.
Future Plans for RespireRx
RespireRx is proactive in its responses post-revocation. The company is gearing up to file a Form 10 registration, which is consistent with their intentions to keep investors informed and engaged. This process will involve comprehensive documentation, including two years of audited financial statements, expected to be filed after a key date at the end of 2025.
With their preparation on track, the adjustment period after the revocation provides the opportunity to submit more thorough analyses and operational updates, which must be adhered to after filing to ensure compliance with future SEC expectations.
About RespireRx Pharmaceuticals Inc.
RespireRx is committed to discovering and developing groundbreaking treatments for various neurological and psychiatric disorders. With a specialized focus on improving outcomes for patients with epilepsy, ADHD, obstructive sleep apnea, and severe spinal cord injuries, the company is enhancing its research to drive innovative solutions.
The company has developed a pipeline that includes neuromodulators like GABAkines and AMPAkines, alongside pharmaceutical cannabinoids targeted for specific therapeutic needs. Each of these compounds aims to provide more effective treatments compared to those currently available on the market.
Innovations in Drug Development
RespireRx's two primary drug platforms seek to revolutionize treatment modalities in psychiatry. Firstly, the development of AMPAkines presents a unique and novel approach in addressing ADHD symptoms with fewer side effects than traditional stimulants. Additionally, GABAkines are exploring new paths in the treatment of conditions like epilepsy with promising preclinical results.
The company also has a vested interest in ResolutionRx, its subsidiary focusing on obstructive sleep apnea, with studies already demonstrating efficacy in Phase 2 trials. Overall, these developments highlight RespireRx's commitment to transforming patient care through innovative drug solutions.
Frequently Asked Questions
What is the significance of the SEC's order for RespireRx?
The SEC's order revoked RespireRx's registration of securities, highlighting compliance issues with periodic reporting requirements, which impacts its trading status.
What does RespireRx plan following the SEC order?
The company intends to file a Form 10 registration, which will include two years of audited financial statements to regain compliance and market access.
What are the upcoming research priorities for RespireRx?
Research will focus on neurological and psychiatric conditions with a deep dive into drug development for ADHD, epilepsy, and sleep apnea treatments.
How does RespireRx position itself in the pharmaceutical landscape?
RespireRx aims to innovate with its unique drug platforms and compounds, addressing unmet medical needs and differentiating itself in the competitive market.
Who should be contacted for more information about RespireRx?
For inquiries, Jeff Margolis, the Senior Vice President and CFO, can be reached via email or through the RespireRx corporate website.
